Vaxxas Secures TGA Manufacturing License for Revolutionary Microarray Patch Vaccine Technology
核心洞察
Australian biotech company Vaxxas (搜索) has received a TGA manufacturing license for its high-density microarray patch (HD-MAP) technology, enabling GMP production for clinical trials.
The HD-MAP technology has demonstrated safety and tolerability in over 750 participants across six first-in-human trials, showing equal or greater immune responses at lower doses.
The patch-based vaccine delivery system reduces cold-chain requirements and enables self-administration, potentially transforming global vaccine access and distribution.
Australian biotechnology company Vaxxas (搜索) has secured a manufacturing license from the Therapeutic Goods Administration (TGA) to produce its proprietary high-density microarray patch (HD-MAP) technology for clinical trials at its Brisbane facility. The milestone enables Good Manufacturing Practice (GMP) production and positions the company to advance its needle-free vaccine delivery platform toward commercialization.
Revolutionary Patch Technology Shows Clinical Promise
The HD-MAP technology comprises thousands of microscopic projections molded into a small patch, with each microprojection printed with a dried vaccine formulation. When applied to the skin, the patch delivers vaccines directly to immune cells (搜索) residing just beneath the skin surface. This targeted delivery approach has demonstrated the potential to achieve stronger immune protection with smaller doses compared to traditional injection methods.
Clinical data from six first-in-human trials involving more than 750 participants have shown strong safety, tolerability, and robust immune responses. Previous studies have demonstrated that HD-MAP delivery induces equal or greater immune responses to injected vaccines at lower doses, while maintaining stability at higher temperatures than liquid vaccine formulations.
Addressing Global Vaccination Challenges
The technology addresses key barriers to vaccine access worldwide by reducing cold-chain storage requirements and enabling self-administration. "By reducing cold-chain requirements and enabling self-administration, this innovation addresses key barriers to vaccine access and uptake worldwide," said Vaxxas (搜索) Chair Sarah Meibusch.
The HD-MAP has been tested across multiple vaccine types, including COVID-19 (搜索), seasonal and pre-pandemic influenza (搜索), and measles (搜索) and rubella (搜索) vaccines. This versatility positions the platform as a potential universal delivery solution for vaccine self-administration, designed to enable future home delivery.
Manufacturing Capabilities and Strategic Partnerships
The TGA manufacturing license for aseptic production includes principles and procedures to ensure vaccines meet high quality standards as defined by TGA and GMP requirements. The company has installed its first robotic lines for sterile manufacture at its state-of-the-art biomedical facility in Brisbane.
Vaxxas (搜索) has developed its technology with support from global partners including SK bioscience (搜索), the US Government, the Wellcome Trust, and the Gates Foundation (搜索). Chief Technology Officer Dr. Angus Forster noted that the license "unlocks the way forward for Vaxxas to continue developing our world-leading HD-MAP technology" while contributing to Queensland's growing biotech sector.
Market Potential and Future Development
The technology has the potential to disrupt the multibillion-dollar global vaccine market by improving access, reducing costs, and expanding vaccination coverage. Preclinical and clinical data demonstrate the platform's ability to deliver all major vaccine types, positioning it as a comprehensive solution for vaccine delivery challenges.
The HD-MAP vaccines remain under investigation and are available only for investigational uses, with no current commercial availability worldwide. Vaxxas (搜索) continues advancing its lead programs toward commercialization while expanding its manufacturing capabilities to support future clinical development.